Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalassemia intermedia

C Camaschella1, M D Cappellini

  • 1Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale S. Luigi Gonzaga, Italy.

Haematologica
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects.

Annals of hematology·2022
Same author

Iron deficiency anaemia revisited.

Journal of internal medicine·2019
Same author

Clinical outcomes of Clostridium difficile infection according to strain type. A prospective study in medical wards.

European journal of internal medicine·2018
Same author

Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).

Annals of hematology·2017
Same author

Transcranial color Doppler in stroke-free adult patients with sickle cell disease.

Annals of hematology·2017
Same author

Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group.

Molecular genetics and metabolism reports·2017
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Thalassemia intermedia is a milder form of thalassemia, but current diagnostic criteria are insufficient. Molecular defect typing aids diagnosis, though genotype doesn't always predict phenotype, necessitating careful patient follow-up.

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Thalassemia intermedia presents a milder phenotype than thalassemia major.
  • Existing diagnostic criteria (age, hemoglobin levels, transfusion status) are inadequate.
  • Molecular defect typing offers a new diagnostic approach.

Purpose of the Study:

  • To evaluate the effectiveness of molecular defect typing for diagnosing thalassemia intermedia.
  • To explore the relationship between beta-genotype and clinical phenotype.
  • To highlight the need for accurate follow-up due to potential complications.

Main Methods:

  • Retrospective analysis of patients with thalassemia intermedia.
  • Molecular defect typing to identify genetic variations.

Related Experiment Videos

  • Phenotypic assessment including clinical presentation and hemoglobin levels.

    • Main Results:

    • Molecular typing provides a valuable tool for diagnosing thalassemia intermedia.
    • Beta-genotype alone is not fully predictive of phenotype due to interacting factors.
    • Thalassemia intermedia patients experience complications requiring vigilant monitoring.

    Conclusions:

    • Current diagnostic criteria for thalassemia intermedia are unsatisfactory.
    • Molecular defect analysis improves diagnostic accuracy.
    • Despite a generally benign course, complications necessitate careful management and follow-up.
    • Future therapies may involve pharmacological manipulation of hemoglobin switching.